Durvalumab

Durvalumab
Monoclonal antibody
Type	?
Source	Human
Target	CD274
Identifiers
CAS Number	1428935-60-7
ATC code	None
IUPHAR/BPS	7985
ChemSpider	none
Chemical data
Formula	C₆₅₀₂H₁₀₀₁₈N₁₇₄₂O₂₀₂₄S₄₂
Molar mass	146.3 kDa

Durvalumab^[1] is a monoclonal antibody designed for the treatment of cancer.^[2] It targets programmed death ligand-1 (PD-L1).^[3]

This drug was developed by MedImmune.

Clinical trials

A phase 1B clinical trial of durvalumab and tremelimumab for non-small cell lung cancer (NSCLC) reported encouraging results for PD-L1 positive and negative patients.^[3]

References

↑ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information 28 (4).
↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Durvalumab, American Medical Association.
1 2 ASTRAZENECA’S COMBINATION OF DURVALUMAB WITH TREMELIMUMAB SHOWS CLINICAL ACTIVITY IN NON-SMALL CELL LUNG CANCER IRRESPECTIVE OF PD-L1 STATUS. Feb 2016

Monoclonal antibodies for the immune system

Immune system ("-l(i[m])-")

Human ("-limu-")	immunosuppression: Abrilumab Adalimumab Anifrolumab Atorolimumab Belimumab Brodalumab Carlumab Dupilumab Durvalumab Eldelumab Fresolimumab Golimumab Lerdelimumab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oxelumab§ Placulumab Sarilumab Sifalimumab Tabalumab Ulocuplumab Varlilumab immune activation: Ipilimumab Nivolumab Pembrolizumab Tremelimumab Urelumab other: Bertilimumab Zanolimumab

Mouse ("-limo-")	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox

Chimeric ("-lixi-")	Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab

Humanized ("-lizu-")	immunosuppressive: Aselizumab Apolizumab Benralizumab^† Cedelizumab Certolizumab pegol Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab Fontolizumab Itolizumab Lampalizumab Ligelizumab Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab PRO 140^† Reslizumab Rontalizumab Rovelizumab Ruplizumab Quilizumab Samalizumab Siplizumab Talizumab Teplizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab TGN1412^§ non-immunosuppressive: Ibalizumab^†

Chimeric + humanized ("-lixizu-")	Otelixizumab

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab

Humanized ("-kizu-", "-kinzu-")	Anrukinzumab Clazakizumab Enokizumab Gevokizumab Ixekizumab Lebrikizumab Olokizumab Perakizumab Tildrakizumab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Tuesday, February 09, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.